Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialA phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target – Share XLilly’s mirikuzumab hits target in phase 3 ulcerative colitis trialhttps://pharmaphorum.com/news/lillys-mirikuzumab-hits-target-in-phase-3-ulcerative-colitis-trial/
Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyMerck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for Share XMerck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyhttps://pharmaphorum.com/news/merck-takes-on-lilly-nektar-in-il-2-with-1-85bn-pandion-buy/
BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitisBristol-Myers Squibb’s commercial hopes for new multiple sclerosis drug Zeposia have yet to bear fruit thanks to the Share XBMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitishttps://pharmaphorum.com/news/bms-eyes-may-fda-verdict-for-ms-drug-zeposia-in-ulcerative-colitis/
GSK suffers another R&D setback, axing ulcerative colitis drug trialGlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in Share XGSK suffers another R&D setback, axing ulcerative colitis drug trialhttps://pharmaphorum.com/news/gsk-suffers-another-rd-setback-axing-ulcerative-colitis-drug-trial/
Open communication helps ulcerative colitis patients through COVID-19Gastroenterologist Dr Séverine Vermeire explains how lockdowns and communication changes over COVID-19 are taking their toll on ulcerative Share XOpen communication helps ulcerative colitis patients through COVID-19https://pharmaphorum.com/views-analysis-patients/open-communication-helps-ulcerative-colitis-patients-through-covid-19/
Data sets up ulcerative colitis expansion for BMS’ MS drug ZeposiaBristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – Share XData sets up ulcerative colitis expansion for BMS’ MS drug Zeposiahttps://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/
Despite biosims, ulcerative colitis drugs still cost too much; ICERNone of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough Share XDespite biosims, ulcerative colitis drugs still cost too much; ICERhttps://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/
Analysts question Gilead’s commitment to arthritis drug after FDA setbackThe FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage Share XAnalysts question Gilead’s commitment to arthritis drug after FDA setbackhttps://pharmaphorum.com/news/gilead-could-become/
Roche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outRoche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans Share XRoche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outhttps://pharmaphorum.com/news/roches-ulcerative-colitis-drug-etrolizumab-looks-shaky-after-data-roll-out/
